

Introduction

We are pleased to share our Clinical Laboratories Industry Multiples Valuation Update for Q3 2024.

At Seale & Associates, we are committed to providing process-driven solutions designed to optimize value and achieve our client's strategic objectives in a range of transactions, including Mergers, Acquisitions, Divestitures and Carve-Outs, Business Sales, Recapitalizations, and Joint Ventures, among other corporate finance and strategy consulting services.

Over the course of 25+ years, we have successfully served clients all over the world, and we are delighted to continue providing investment banking advisory services to our clients who are looking to grow through acquisitions or optimize their portfolios through strategic divestitures.

Seale has extensive experience advising leading multinational companies, private equity firms, and family-owned businesses across a wide range of industries.



James A. Seale | President jseale@sealeassociates.com



Brett M. Carmel | Senior Managing Director bcarmel@sealeassociates.com



Robert Whitney | Managing Director rwhitney@sealeassociates.com



Sergio Garcia del Bosque | Managing Director sgarcia@sealeassociates.com



Carlos Hernández Goudet | Managing Director chernandez@sealeassociates.com



Alejandro Montemayor | Vice President amontemayor@sealeassociates.com



Armando Rios | Vice President arios@sealeassociates.com




Clinical Labs Industry Overview, M&A Trends and Market Intelligence

Key M&A Trends Shaping the Industry

- Companies are increasingly pursuing M&A opportunities to integrate artificial intelligence (AI) and digital capabilities. These technologies are sought to enhance diagnostic accuracy and operational efficiency, positioning firms for stronger growth and improved patient outcomes in 2024
- There is a significant interest from private equity firms in acquiring clinical laboratory services. These investments are motivated by the stable cash flows and growth potential of these services, particularly in the wake of increasing demand for diagnostic tests and personalized medicine
- The independent laboratory segment is experiencing huge consolidation as players focus on strategic partnerships and collaborations, which will drive the market's growth
- Large organizations, including those with clinical laboratory services, are actively divesting non-core assets. Thhis strategy is intended to reduce Research & Development expenses and generate cash to fund new investments that align more closely with their core competencies
- As clinical labs face increasing pressure to optimize margins and adapt to
 evolving regulations, the integration of laboratory information systems
 (LIS) with billing systems is emerging as a critical solution. These
 platforms streamline workflows, reduce errors, and improve billing
 accuracy, enabling labs to enhance financial performance while scaling
 efficiently

Clinical Laboratories Industry Market Size



Clinical Laboratories Market Trends



Adoption of next-generation sequencing (NGS), digital pathology, and artificial intelligence (AI) is **enhancing diagnostic accuracy** and **efficiency**



Increased automation to improve **efficiency**, **reduce turnaround times**, and **minimize errors**



Emphasis on **affordable diagnostic solutions** through centralized networks and advanced technologies



Enhanced collaboration between **public health institutions** and **private labs** to improve access to advanced diagnostic services



Growth in emerging markets with **investments** in **healthcare infrastructure** and **increased accessibility** to diagnostic services

Clinical Laboratories Industry Global Comparable Public Companies

| Company | | Couloting | Market | Enterprise | Revenue | EBITDA | Annual Average EV/EBITDA | | Third Quarter Sep. 30, 2024 | |
|-------------------------------------|---|-----------|---------------|----------------|---------|----------------|-----------------------------|----------------|--------------------------------|----------------|
| Company | | Country | Cap. US\$M | Value US\$M | US\$M | Margin | 2022 | 2023 | EV/ EBITDA | EV/ Revenue |
| Alliança Saúde e Participações S.A. | alliar médicos à frente sistema de diagnósticos de saúde | BRA | \$334 | \$492 | \$221 | 9.9% | 19.5x | 35.4x | 22.5x | 2.2x |
| Capitol Health Limited | CAPITOLHEALTH | AUS | \$270 | \$353 | \$163 | 20.9% | 11.2x | 10.4x | 10.4x | 2.2x |
| Dian Diagnostics Group Co.,Ltd. | 迪安诊断 DIAN DIAGNOSTICS | CHN | \$1,190 | \$1,817 | \$1,764 | 10.2% | 7.0x | 6.2x | 10.1x | 1.0x |
| Fleury S.A. | fleury medicina e saúde | BRA | \$1,546 | \$2,138 | \$1,387 | 25.8% | 7.3x | 8.5x | 6.0x | 1.5x |
| Healius Limited | ı:ı healius | AUS | \$868 | \$1,935 | \$1,211 | 19.1% | 5.4x | 7.5x | 8.4x | 1.6x |
| H.U. Group Holdings, Inc. | HU H.U.GROUP | JPN | \$1,052 | \$1,325 | \$1,678 | 6.7% | 3.1x | 4.8x | 11.8x | 0.8x |
| Integral Diagnostics Limited | integral | AUS | \$482 | \$700 | \$326 | 18.9% | 13.5x | 12.6x | 11.4x | 2.2x |
| Krsnaa Diagnostics Limited | Krsnad DIAGNOSTICS LET'S DO GOOD | IND | \$325 | \$337 | \$81 | 22.8% | 12.1x | 13.6x | 18.2x | 4.7x |
| Med Life S.A. | WedLife | ROM | \$728 | \$1,072 | \$575 | 13.3% | 12.1x | 13.9x | 14.0x | 1.9x |
| Excluded from mean and median | | | | | | Mean Median | 9.8x 11.2x | 10.4x 10.4x | 11.0x 11.4x | 1.8x 1.9x |

Seale & Associates

Clinical Laboratories Industry Global Comparable Public Companies

| Company | | Country | Market Cap. | Enterprise Value | Revenue | EBITDA | Annual Average EV/EBITDA | | Third Quarter Sep. 30, 2024 | |
|---|------------|---------|----------------|---------------------|----------|--------|-----------------------------|-------|--------------------------------|----------------|
| Company | | Country | US\$M | US\$M | US\$M | Margin | 2022 | 2023 | EV/ EBITDA | EV/ Revenue |
| Eurofins Scientific SE | eurofins 💸 | LUX | \$12,016 | \$15,270 | \$7,499 | 21.7% | 9.7x | 9.8x | 9.4x | 2.0x |
| Labcorp Holdings Inc. | labcorp | USA | \$18,764 | \$24,569 | \$12,713 | 15.2% | 7.0x | 9.3x | 12.7x | 1.9x |
| Medicover AB (publ) | | SWE | \$2,819 | \$4,019 | \$2,228 | 12.9% | 12.8x | 13.9x | 14.0x | 1.8x |
| Quest Diagnostics Incorporated Quest Diagnostics Incorporated | | USA | \$17,282 | \$22,217 | \$9,539 | 22.7% | 6.6x | 9.0x | 10.2x | 2.3x |
| RadNet, Inc. | | USA | \$5,132 | \$6,320 | \$1,773 | 20.9% | 8.1x | 10.6x | 17.0x | 3.6x |
| Sonic Healthcare Limited | | AUS | \$9,066 | \$11,859 | \$6,217 | 17.4% | 7.0x | 9.0x | 11.0x | 1.9x |
| Excluded from mean and median | | | | | | Mean | 7.7x | 9.5x | 11.5x | 2.0x |
| | | | | | | Median | 7.5x | 9.5x | 11.8x | 2.0x |

Clinical Laboratories - Global Transactions

| Date | Target | Country | Description | Buyer | Seller | % Acquired | Size US\$M | EV/ EBITDA | EV/ Revenue |
|---------|---------------------------------|---------|--|-----------------------------|------------------|------------|---------------|---------------|----------------|
| Sep-24 | GENETICS & IVF Institute | USA | Amulet Capital Partners , a private equity firm, acquired Genetics & IVF Institute , a provider of reproductive tissue banking and related reproductive technology services | AMULET CAPITAL PARTNERS LP | - | 100.0% | - | - | - |
| Sep-24 | GenoStaff ジェノスタッフ株式会社 | JPN | RORZE Lifescience , a company specializing in life science automation solutions, acquired Genostaff , a provider of molecular pathology analysis services, to enhance its capabilities in molecular pathology | RORZE Lifescience | - | 100.0% | - | - | - |
| Sep-24 | SYNLAB Lietuva UAB | LTU | Affidea Lietuva , a provider of polyclinics, advanced diagnostic imaging, acquired SYNLAB Lietuva , a laboratory network, to expand its laboratory services and offer integrated outpatient services | affidea | SYNLAB | 100.0% | - | - | - |
| Aug-24 | Biostat Imaging LLC | USA | Principle Health Systems , a provider of mobile laboratory services to long-term care facilities, acquired BioStat Imaging , a mobile imaging provider, to offer a one-stop solution for both laboratory and imaging needs | PRINCIPLE HEALTH SYSTEMS | - | 100.0% | - | - | - |
| Aug-24* | agilus >>> diagnostics | IND | Fortis Healthcare, a provider of integrated healthcare services, announced the acquisition of a minority stake in Agilus Diagnostics , a diagnostics company | Fortis | Multiple Sellers | 31.5% | - | - | - |

^{*}Announced transactions pending approval and other customary closing conditions

Sign up for M&A insights

We deliver sector-specific intelligence designed specifically for industry leaders, private equity firms, and their advisors. Our industry reports and featured articles deliver real-time access to key industry data, including:



Emerging industry trends

Quarterly reports covering 30+ industries

Monthly reports for the U.S., Mexico, and Colombia

Transaction analysis and market trends

Valuable insights for industry leaders

Receive email updates with our proprietary data, reports, and insights as they are published for the industries that matter to you the most

SUBSCRIBE

Global M&A Representative Engagements



HOLDINGS













































JAMES A. SEALE President and Founder | Washington, DC



+1 (703) 623-9253

32+ years of global M&A experience, Attorney, CPA Arthur Andersen, and Professor of Global Investment Banking at George Washington University University of Virginia - JD University of Kentucky - BS in Accounting



SERGIO GARCIA DEL BOSQUE Managing Director | Mexico City, Mexico



+52 (55) 8000-7463

16+ years of global M&A experience IPADE - MBA Instituto Tecnologico y de Estudios Superiores de Monterrey BS in Industrial Engineering




CARLOS HERNANDEZ GOUDET Managing Director | San Luis Potosi, Mexico



+1 (571) 482-3432

14+ years of global M&A experience Columbia University - MBA Instituto Tecnologico y de Estudios Superiores de Monterrey BS in Industrial Engineering







BRETT M. CARMEL

Senior Managing Director and Co-founder | Miami, FL



+1 (703) 294-6530

25+ years of global M&A experience and Professor of M&A at Johns Hopkins University

The George Washington University - MBA International Business and MA - International Affairs

University of Florida - BA in Political Science with High Honors



ROBERT E. WHITNEY Managing Director | Washington, DC





+1 (703) 801-8939

19+ years of global M&A experience, CPA Deloitte & Touche, Corporate Audit and Assurance Services University of Richmond - BS Business Administration in Accounting




FELIPE BUENO


Senior Director | Monterrey, Mexico




+52 (84) 4432-4444

32+ years with Grupo Industrial Saltillo with experience as Director, Corp. Dev. and extensive global commercial experience Instituto Tecnologico y de Estudios Superiores de Monterrey MBA and BS in Industrial Engineering







Creative Solutions. Trusted Advice.

For over 25 years, Seale & Associates has served leading public and private companies from around the world and operating in a broad range of industries with a high level of quality, integrity and independence while presenting innovative ideas and trusted solutions to address their most complex dealings.

25

YEARS OF EXPERIENCE

\$50B+

TRANSACTIONS GLOBALLY

SERVICES AND SOLUTIONS

Mergers & Acquisitions

Divestitures

held companies.

Joint Ventures / Alliances

Recapitalizations

Due Diligence / Support

Expert Witness Testimony

Corporate Finance Advisory

Strategy Consulting

Trusted Advisor to Leading Companies Worldwide

We have worked repeatedly with many of the most well-known companies in the world...











































...as well as with reputable funds, family-offices and privately





























Seale & Associates

Creative Solutions. Trusted Advice.